Remedy is experiencing a strong debut on the KOSDAQ, with shares rising over 30% on their first day of trading.
According to the Korea Exchange, as of 9:19 a.m., Remedy's stock was trading at 27,700 won, up 7,000 won (33.82%) from the initial public offering price of 20,700 won. Early in the session, shares peaked at 33,000 won, representing a nearly 59.4% increase from the IPO price, before giving back some gains.
Remedy develops medical handheld X-ray devices, industrial non-destructive testing equipment, and key X-ray components based on its proprietary low-dose, miniaturized, high-resolution X-ray technology. The company is expanding its business into medical, industrial, and specialized markets, leveraging its full-stack technology that encompasses everything from core components to finished products.
Funds raised from the IPO will be allocated to enhancing research and development (R&D), increasing production capacity, and strengthening its global sales network. The company also plans to introduce automated equipment and integrate artificial intelligence (AI) solutions to evolve into a global X-ray platform enterprise.
Previously, Remedy achieved a competitive ratio of 1,146 to 1 during the institutional investor demand forecast held from June 17 to 23, setting the IPO price at the upper end of the desired range of 18,000 to 20,700 won. In the general subscription held on July 1 and 2, the company recorded a competitive ratio of 1,707 to 1, with subscription deposits totaling approximately 5.3 trillion won. KB Securities served as the underwriter for the listing.
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.